Three‐year recurrence‐free survival in a patient with recurrent medulloblastoma after resection, high‐dose chemotherapy, and intrathecal Yttrium‐90‐labeled DOTA 0 ‐D‐Phe 1 ‐Tyr 3 ‐octreotide radiopeptide brachytherapy

Three‐year recurrence‐free survival was obtained in a boy age 8 years with recurrent medulloblastoma of the cauda equina that expressed somatostatin type 2 receptors. The combination of conventional and high‐dose chemotherapy, surgery, and intrathecal targeted radiotherapy with an Yttrium 90‐labeled octreotide analogue warrants a controlled trial for this difficult condition.